Conference Day One - Wednesday November 5, 2025
8:00 am Check-In & Light Breakfast
8:55 am Chair’s Opening Remarks
Contextualizing Inflammasome-Related Disease Pathogenesis to Unveil Clinical Milestones
9:00 am Targeting NLRP3 in Myelodysplastic Syndrome: Initial Results from Phase Ib Trial of DFV890
Synopsis
- Demonstrating NLRP3 pathway engagement through decreased systemic inflammatory cytokines and biomarker activity
- Evaluating the therapeutic potential of NLRP3 inhibition in earlier-stage MDS patients to enhance clinical response
- Investigating the link between inflammatory signaling and CHIP-associated mutations
9:30 am Preclinical & Clinical Evaluation of the Brain Penetrant NLRP3 Inhibitor, NT-0796 in Obesity & Cardiometabolic Disease
Synopsis
- Highlighting favorable shifts in cardiovascular biomarkers linked to reduced inflammation-driven cardiometabolic risk
- Underscoring the role of hypothalamic inflammation as a therapeutic target in obesity
- Showcasing oral NLRP3 inhibition as a strategy to improve key metabolic parameters in individuals with obesity
10:00 am Speaking Position Reserved for Alamar Biosciences
11:00 am Morning Refreshments & Speed Networking
Synopsis
A fulfilling opportunity to make the most of in-person networking and strengthen your connections within the critical landscape of biopharmaceutical companies advancing inflammasome-targeted therapeutics. Designed to maximize your presence with industry peers and leading researchers in the field.
Harnessing Mechanism-Based Biomarkers to Translate Inflammasome Activity into Clinical Efficacy
11:30 am NLRP3-Mediated Inflammation: Novel Strategy for Neurodegenerative & Cardiometabolic Disease Intervention
Synopsis
- Characterizing NLRP3-driven inflammatory pathways across neurodegenerative and cardiometabolic diseases
- Advancing development of VTX3232 as a CNS-penetrant oral NLRP3 inhibitor to address high unmet clinical needs
- Demonstrating IL-1B and IL-6 modulation as a mechanism to impact both central and peripheral inflammation in patient populations
12:00 pm A New Predictive Frontier: Cellular-Level Inflammasome Biomarkers in Traumatic Brain Injury
Synopsis
- Shifting from traditional blood-based to cellular-level biomarker analysis in traumatic brain injury
- Isolating and profiling immune cells to measure inflammasome activation
- Linking cellular inflammasome markers to patient outcomes including coma recovery predictions
12:30 pm Lunch & Networking
Cracking the Molecular Mechanisms to Reframe Inflammasome Research on Novel Targets
1:30 pm Targeting Innate Immunity: Inflammasomes & Myeloid Cells in Chronic Inflammation & Tissue Repair
Synopsis
- Introducing novel innate immune targets to explore the role of myeloid cells in tissue repair and chronic inflammatory conditions
- Examining translational challenges of inflammasome biology in clinical settings for inflammatory and fibrotic disorders
- Highlighting pharmacological strategies with immune biology to guide future therapeutic innovations
2:00 pm A Mechanistic Deep Dive: Tackling the Molecular Interplay with Caspases, Apoptosis & Pyroptosis
Synopsis
- Describing the dual role of mitochondrial metabolism in driving NLRP3 activity and inflammation while blocking caspase-dependent apoptosis
- Illuminating how programmed cell death pathways interact and why pyroptosis might override apoptotic signals
- Discussing how dysregulation in apoptosis and pyroptosis shapes therapeutic opportunities through targeting of these interactions
2:30 pm Afternoon Refreshments & Poster Session
Building a Future-Proof Indication Strategy to Achieve Long-Term Clinical Success
3:30 pm Strategic Prioritization of Inflammatory Indications: Navigating Risk, Reward & Clinical Feasibility
Synopsis
- Analyzing the trade-offs between orphan inflammatory indications vs larger markets with complex disease heterogeneity
- Reviewing how disease prevalence and competitive activity influences early pipeline decisions
- Unlocking real-world examples on how strategic indication shifts impact drug development opportunities
4:00 pm Fireside Chat: What Each Stakeholder Needs – Repositioning Inflammasome Therapies for Clinical, Commercial & Capital Success
Synopsis
- Exploring the rationale for advancing multiple inflammasome-targeting programs in parallel while managing clinical risk through indication diversity
- Outlining key regulatory requirements for inflammasome-targeting therapeutics (safety pharmacology, dosing windows, and MOA validation)
- Shedding light on how successful Phase II data influences Series B/C financing rounds, partnerships, and acquisition strategies